TIM
NVCR icon

Total Investment Management’s NovoCure NVCR Stock Holding History

Total Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$18 – 599
2025
Q2 		$18 Buy
+1
New +$17 ﹤0.01% 886

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Total Investment Management's NVCR Position: Q3 2025 in Review

Total Investment Management sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 1 share — an estimated $18 sold.

Total Investment Management first reported a position in NVCR in Q2 2025 and held it in 1 quarter. The position peaked at $18 in Q2 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Total Investment Management reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Total Investment Management sold 1 NovoCure share in Q3 2025, an estimated $18.
  • Total Investment Management first reported a position in NovoCure in Q2 2025 and held it in 1 quarter.
  • Total Investment Management's NovoCure position peaked at $18 in Q2 2025.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Total Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.